Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression

Journal of Molecular Biology

Volumn 422, Issue 4, 2012, Pages 532-544

  Spangler, Jamie B ^a   Manzari, Mandana T ^a   Rosalia, Elizabeth K ^b   Chen, Tiffany F ^a   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

cancer; downregulation; ErbB1; fibronectin; multispecific

Indexed keywords

ANTIBODY 10TH TYPE 3 DOMAIN OF HUMAN FIBRONECTIN FUSION PROTEIN; ANTINEOPLASTIC AGENT; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; K RAS PROTEIN; MEMBRANE FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CLUSTER ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; INTERNALIZATION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR XENOGRAFT;

EID: 84865513993     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.06.014     Document Type: Article

References (40)

1. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev., Mol. Cell Biol. 2 2001 127 137 (Pubitemid 33674041)
2. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit. Rev. Oncol./Hematol. 19 1995 183 232
3. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur. J. Cancer 37 2001 S9 S15
4. E. Martinelli, R. De Palma, M. Orditura, F. De Vita, and F. Ciardiello Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy Clin. Exp. Immunol. 158 2009 1 9
5. G. Bollag, and F. McCormick Regulators and effectors of ras proteins Annu. Rev. Cell Biol. 7 1991 601 632
6. E. Vakiani, and D.B. Solit KRAS and BRAF: drug targets and predictive biomarkers J. Pathol. 223 2011 219 229
7. A. Lievre, J.B. Bachet, D. Le Corre, V. Boige, B. Landi, and J.F. Emile KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res. 66 2006 3992 3995
8. R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, and D.J. Freeman Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J. Clin. Oncol. 26 2008 1626 1634
9. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, and P. Saletti Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J. Clin. Oncol. 26 2008 5705 5712
10. L.M. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi, and S.S. Bacus Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy Proc. Natl Acad. Sci. USA 102 2005 1915 1920 (Pubitemid 40261987)
11. M.W. Pedersen, H.J. Jacobsen, K. Koefoed, A. Hey, C. Pyke, J.S. Haurum, and M. Kragh Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy Cancer Res. 70 2010 588 597
12. J.B. Spangler, J.R. Neil, S. Abramovitch, Y. Yarden, F.M. White, D.A. Lauffenburger, and K.D. Wittrup Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling Proc. Natl Acad. Sci. USA 107 2010 13252 13257
13. R.C. Roovers, M.J. Vosjan, T. Laeremans, R. El Khoulati, R.C. de Bruin, and K.M. Ferguson A bi-paratopic anti-EGFR nanobody efficiently inhibits solid tumour growth Int. J. Cancer 129 2011 2013 2024
14. A. Koide, and S. Koide Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain Methods Mol. Biol. 352 2007 95 109
15. B.J. Hackel, J.R. Neil, F.M. White, and K.D. Wittrup Epidermal growth factor receptor downregulation by small heterodimeric binding proteins Protein Eng., Des. Sel. 25 2012 47 57
16. J. Downward, M.D. Waterfield, and P.J. Parker Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity J. Biol. Chem. 260 1985 14538 14546 (Pubitemid 16210976)
17. B.L. Margolis, I. Lax, R. Kris, M. Dombalagian, A.M. Honegger, and R. Howk All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor J. Biol. Chem. 264 1989 10667 10671 (Pubitemid 19161640)
18. K. Sato, A. Sato, M. Aoto, and Y. Fukami c-Src phosphorylates epidermal growth factor receptor on tyrosine 845 Biochem. Biophys. Res. Commun. 215 1995 1078 1087
19. J.L. Countaway, A.C. Nairn, and R.J. Davis Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase J. Biol. Chem. 267 1992 1129 1140
20. S.K. Kuwada, K.A. Lund, X.F. Li, P. Cliften, K. Amsler, L.K. Opresko, and H.S. Wiley Differential signaling and regulation of apical vs. basolateral EGFR in polarized epithelial cells Am. J. Physiol. 275 1998 C1419 C1428
21. N. Normanno, C. Bianco, A. De Luca, M.R. Maiello, and D.S. Salomon Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment Endocr.-Relat. Cancer 10 2003 1 21 (Pubitemid 36457237)
22. N. Normanno, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, and A. De Luca The ErbB receptors and their ligands in cancer: an overview Curr. Drug Targets 6 2005 243 257 (Pubitemid 40667793)
23. E.J. Joslin, L.K. Opresko, A. Wells, H.S. Wiley, and D.A. Lauffenburger EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation J. Cell Sci. 120 2007 3688 3699 (Pubitemid 350120960)
24. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin. Cancer Res. 1 1995 1311 1318
25. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, and K.M. Ferguson Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 2005 301 311 (Pubitemid 40544648)
26. J. Griggs, and K. Zinkewich-Peotti The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy Br. J. Cancer 101 2009 1807 1812
27. W. Zhang, M. Gordon, A.M. Schultheis, D.Y. Yang, F. Nagashima, and M. Azuma FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab J. Clin. Oncol. 25 2007 3712 3718 (Pubitemid 47372612)
28. R.L. Shields, A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, and J. Briggs High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR J. Biol. Chem. 276 2001 6591 6604
29. A. Sorkin, and L.K. Goh Endocytosis and intracellular trafficking of ErbBs Exp. Cell Res. 315 2009 683 696
30. J.X. Zhu, S. Goldoni, G. Bix, R.T. Owens, D.J. McQuillan, C.C. Reed, and R.V. Iozzo Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis J. Biol. Chem. 280 2005 32468 32479 (Pubitemid 41361859)
31. W.W. Chen, B. Schoeberl, P.J. Jasper, M. Niepel, U.B. Nielsen, D.A. Lauffenburger, and P.K. Sorger Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data Mol. Syst. Biol. 5 2009 239
32. K. Scheffzek, M.R. Ahmadian, W. Kabsch, L. Wiesmuller, A. Lautwein, F. Schmitz, and A. Wittinghofer The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants Science 277 1997 333 338 (Pubitemid 27450699)
33. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867 (Pubitemid 38410730)
34. M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, and T. Schneider-Merck Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies Cancer Res. 68 2008 4998 5003
35. H.S. Huang, M. Nagane, C.K. Klingbeil, H. Lin, R. Nishikawa, and X.D. Ji The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling J. Biol. Chem. 272 1997 2927 2935 (Pubitemid 27053343)
36. P.H. Huang, A. Mukasa, R. Bonavia, R.A. Flynn, Z.E. Brewer, and W.K. Cavenee Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma Proc. Natl Acad. Sci. USA 104 2007 12867 12872 (Pubitemid 47255246)
37. J. Mendelsohn Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy Clin. Cancer Res. 3 1997 2703 2707 (Pubitemid 28133130)
38. S.K. Basu, J.L. Goldstein, R.G. Anderson, and M.S. Brown Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts Cell 24 1981 493 502
39. M. Ishiyama, H. Tominaga, M. Shiga, K. Sasamoto, Y. Ohkura, and K. Ueno A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet Biol. Pharm. Bull. 19 1996 1518 1520 (Pubitemid 26403266)
40. K. Hamasaki, K. Kogure, and K. Ohwada A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt Toxicon 34 1996 490 495 (Pubitemid 26130128)